Literature DB >> 18093202

Cutaneous compression for the laser treatment of epidermal pigmented lesions with the 595-nm pulsed dye laser.

Jerome M Garden1, Abnoeal D Bakus, Yacov Domankevitz.   

Abstract

BACKGROUND: The 595-nm pulsed dye laser has been the standard of care for many vascular lesions and has rarely been used in the treatment of epidermal pigmented lesions.
OBJECTIVE: The objective was to investigate the effectiveness and safety of a compression technique for the treatment of epidermal pigmented lesion using a modified 595-nm pulsed dye laser with no epidermal cooling.
METHODS: Twelve subjects (mean age 58 years) underwent treatments using a modified 595-nm dye laser with a compression handpiece and no epidermal cooling. Treatments were performed with radiant exposures of 7 to 12 J/cm(2), 7-mm spot size, and 1.5-ms pulse duration. Each subject received one to four treatments, 4 to 6 weeks apart. Follow-up evaluations were held before each treatment and 4 months after last treatment.
RESULTS: Clearance of 75% to 100% was obtained in 43, 59, 76, and 79% of the lesions treated after one, two, three, and four treatments respectively. The fourth treatment was evaluated 4 months posttreatment. Side effects included immediate erythema and edema and rare cases of transient hyperpigmentation and atrophy. No purpura and long-lasting side effects were observed.
CONCLUSION: The compression technique with a modified 595-nm pulsed dye laser system is effective and safe for the treatment of epidermal pigmented lesions.

Entities:  

Mesh:

Year:  2007        PMID: 18093202     DOI: 10.1111/j.1524-4725.2007.34035.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  1 in total

1.  Efficacy and safety of long-pulse pulsed dye laser delivered with compression versus cryotherapy for treatment of solar lentigines.

Authors:  Hassan Seirafi; Soheil Fateh; Farshad Farnaghi; Amir H Ehsani; Pedram Noormohammadpour
Journal:  Indian J Dermatol       Date:  2011-01       Impact factor: 1.494

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.